Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?

Chahine LM, Stern MB.

Mov Disord Clin Pract. 2017 Oct 2;4(6):796-805. doi: 10.1002/mdc3.12545. eCollection 2017 Nov-Dec. Review.

2.

Cognition and the course of prodromal Parkinson's disease.

Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2017 Nov;32(11):1640-1645. doi: 10.1002/mds.27189. Epub 2017 Oct 24.

3.

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.

Lim NS, Swanson CR, Cherng HR, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A; PARS Investigators; Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS.

Ann Clin Transl Neurol. 2016 Mar 29;3(5):346-55. doi: 10.1002/acn3.299. eCollection 2016 May.

4.

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2016 Jan;31(1):86-94. doi: 10.1002/mds.26373. Epub 2015 Aug 21.

5.

Natural history of multiple system atrophy in the USA: a prospective cohort study.

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, Tanner CM, Gilman S, Marshall FJ, Wooten F, Racette B, Chelimsky T, Singer W, Sletten DM, Sandroni P, Mandrekar J.

Lancet Neurol. 2015 Jul;14(7):710-9. doi: 10.1016/S1474-4422(15)00058-7. Epub 2015 May 27.

6.

Variants associated with Gaucher disease in multiple system atrophy.

Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Dürr A, Brice A, Takashima H, Kikuchi A, Aoki M, Ishiura H, Yasuda T, Date H, Ahsan B, Iwata A, Goto J, Ichikawa Y, Nakahara Y, Momose Y, Takahashi Y, Hara K, Kakita A, Yamada M, Takahashi H, Onodera O, Nishizawa M, Watanabe H, Ito M, Sobue G, Ishikawa K, Mizusawa H, Kanai K, Hattori T, Kuwabara S, Arai K, Koyano S, Kuroiwa Y, Hasegawa K, Yuasa T, Yasui K, Nakashima K, Ito H, Izumi Y, Kaji R, Kato T, Kusunoki S, Osaki Y, Horiuchi M, Kondo T, Murayama S, Hattori N, Yamamoto M, Murata M, Satake W, Toda T, Filla A, Klockgether T, Wüllner U, Nicholson G, Gilman S, Tanner CM, Kukull WA, Stern MB, Lee VM, Trojanowski JQ, Masliah E, Low PA, Sandroni P, Ozelius LJ, Foroud T, Tsuji S.

Ann Clin Transl Neurol. 2015 Apr;2(4):417-26. doi: 10.1002/acn3.185. Epub 2015 Feb 28.

7.

Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease.

Katz M, Luciano MS, Carlson K, Luo P, Marks WJ Jr, Larson PS, Starr PA, Follett KA, Weaver FM, Stern MB, Reda DJ, Ostrem JL; CSP 468 study group.

Ann Neurol. 2015 Apr;77(4):710-9. doi: 10.1002/ana.24374.

PMID:
25627340
8.

Characterizing Premotor Parkinson's Disease: Clinical Features and Objective Markers.

Chahine LM, Stern MB.

Mov Disord Clin Pract. 2014 Jul 8;1(4):299-306. doi: 10.1002/mdc3.12062. eCollection 2014 Dec. Review.

9.

Undulating Lingual Dyskinesia With Symptomatic Palatal Tremor and Inferior Olivary Hypertrophy Following Cerebellar Hemisphere Hematoma.

Smith KM, Deik A, Stern MB, Thompson P.

Mov Disord Clin Pract. 2014 Jun 11;1(3):245-246. doi: 10.1002/mdc3.12045. eCollection 2014 Sep. No abstract available.

10.

Blood-based biomarkers for Parkinson's disease.

Chahine LM, Stern MB, Chen-Plotkin A.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S99-103. doi: 10.1016/S1353-8020(13)70025-7. Review.

11.

Medication nonadherence in Parkinson's disease.

Fleisher JE, Stern MB.

Curr Neurol Neurosci Rep. 2013 Oct;13(10):382. doi: 10.1007/s11910-013-0382-z. Review. No abstract available.

12.

Impairment of script comprehension in Lewy body spectrum disorders.

Gross RG, Camp E, McMillan CT, Dreyfuss M, Gunawardena D, Cook PA, Morgan B, Siderowf A, Hurtig HI, Stern MB, Grossman M.

Brain Lang. 2013 Jun;125(3):330-43. doi: 10.1016/j.bandl.2013.02.006. Epub 2013 Apr 6.

14.

New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications.

Akhtar RS, Stern MB.

Expert Rev Neurother. 2012 Dec;12(12):1429-38. doi: 10.1586/ern.12.144. Review.

PMID:
23237350
15.

Genetic influences on cognitive decline in Parkinson's disease.

Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A.

Mov Disord. 2012 Apr;27(4):512-8. doi: 10.1002/mds.24946. Epub 2012 Feb 16.

16.

Toward a redefinition of Parkinson's disease.

Stern MB, Lang A, Poewe W.

Mov Disord. 2012 Jan;27(1):54-60. doi: 10.1002/mds.24051. No abstract available.

PMID:
22252891
17.

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K; PARS Investigators.

Mov Disord. 2012 Mar;27(3):406-12. doi: 10.1002/mds.24892. Epub 2012 Jan 11.

18.

Rasagiline in Parkinson's disease.

Chahine LM, Stern MB.

Int Rev Neurobiol. 2011;100:151-68. doi: 10.1016/B978-0-12-386467-3.00008-X. Review.

PMID:
21971007
19.

Development of a non-motor fluctuation assessment instrument for Parkinson disease.

Kleiner-Fisman G, Martine R, Lang AE, Stern MB.

Parkinsons Dis. 2011;2011:292719. doi: 10.4061/2011/292719. Epub 2011 Aug 9.

20.

Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.

Tolosa E, Stern MB.

Eur J Neurol. 2012 Feb;19(2):258-64. doi: 10.1111/j.1468-1331.2011.03484.x. Epub 2011 Aug 5.

PMID:
21819487
21.

Diagnostic markers for Parkinson's disease.

Chahine LM, Stern MB.

Curr Opin Neurol. 2011 Aug;24(4):309-17. doi: 10.1097/WCO.0b013e3283461723. Review.

PMID:
21464716
22.
23.

Introductory remarks on the history and current applications of TCS.

Stern MB.

Int Rev Neurobiol. 2010;90:2-5. doi: 10.1016/S0074-7742(10)90001-9. No abstract available.

PMID:
20692490
24.

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.

Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB.

Neurology. 2010 Aug 3;75(5):448-55. doi: 10.1212/WNL.0b013e3181ebdd79.

25.

Decreased ventral striatal activity with impulse control disorders in Parkinson's disease.

Rao H, Mamikonyan E, Detre JA, Siderowf AD, Stern MB, Potenza MN, Weintraub D.

Mov Disord. 2010 Aug 15;25(11):1660-9. doi: 10.1002/mds.23147.

26.

Parkinson's at risk syndrome: can Parkinson's disease be predicted?

Stern MB, Siderowf A.

Mov Disord. 2010;25 Suppl 1:S89-93. doi: 10.1002/mds.22719.

PMID:
20187248
27.

Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D.

Neurology. 2009 Nov 24;73(21):1738-45. doi: 10.1212/WNL.0b013e3181c34b47.

28.

Premotor Parkinson's disease: clinical features and detection strategies.

Stephenson R, Siderowf A, Stern MB.

Mov Disord. 2009;24 Suppl 2:S665-70. doi: 10.1002/mds.22403. Review.

PMID:
19877244
29.

Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease.

Mavandadi S, Nazem S, Ten Have TR, Siderowf AD, Duda JE, Stern MB, Weintraub D.

Am J Geriatr Psychiatry. 2009 Nov;17(11):986-95. doi: 10.1097/JGP.0b013e3181b215ec.

30.

The scientific and clinical basis for the treatment of Parkinson disease (2009).

Olanow CW, Stern MB, Sethi K.

Neurology. 2009 May 26;72(21 Suppl 4):S1-136. doi: 10.1212/WNL.0b013e3181a1d44c. Review.

PMID:
19470958
31.

Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.

Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V.

Mov Disord. 2009 Jul 30;24(10):1461-7. doi: 10.1002/mds.22571.

32.

Involuntary emotional expression disorder (IEED) in Parkinson's disease.

Phuong L, Garg S, Duda JE, Stern MB, Weintraub D.

Parkinsonism Relat Disord. 2009 Aug;15(7):511-5. doi: 10.1016/j.parkreldis.2009.01.001. Epub 2009 Jan 31.

33.

Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Nazem S, Siderowf AD, Duda JE, Have TT, Colcher A, Horn SS, Moberg PJ, Wilkinson JR, Hurtig HI, Stern MB, Weintraub D.

J Am Geriatr Soc. 2009 Feb;57(2):304-8. doi: 10.1111/j.1532-5415.2008.02096.x. Epub 2008 Dec 10.

34.

Premotor Parkinson's disease: clinical features, detection, and prospects for treatment.

Siderowf A, Stern MB.

Ann Neurol. 2008 Dec;64 Suppl 2:S139-47. doi: 10.1002/ana.21462.

PMID:
19127581
35.

Parkinson's disease: unresolved issues.

Olanow CW, Stern MB.

Ann Neurol. 2008 Dec;64 Suppl 2:S1-2. doi: 10.1002/ana.21442. No abstract available.

PMID:
19127574
36.

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N; Movement Disorder Society UPDRS Revision Task Force.

Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.

PMID:
19025984
37.

Disorders of mood and affect in Parkinson's disease.

Weintraub D, Stern MB.

Handb Clin Neurol. 2007;83:421-33. doi: 10.1016/S0072-9752(07)83019-3. No abstract available.

PMID:
18808926
38.

Suicidal and death ideation in Parkinson's disease.

Nazem S, Siderowf AD, Duda JE, Brown GK, Ten Have T, Stern MB, Weintraub D.

Mov Disord. 2008 Aug 15;23(11):1573-9. doi: 10.1002/mds.22130.

39.

Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Mamikonyan E, Moberg PJ, Siderowf A, Duda JE, Have TT, Hurtig HI, Stern MB, Weintraub D.

Parkinsonism Relat Disord. 2009 Mar;15(3):226-31. doi: 10.1016/j.parkreldis.2008.05.006. Epub 2008 Jul 2.

40.

Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study.

Oehlberg K, Barg FK, Brown GK, Taraborelli D, Stern MB, Weintraub D.

J Geriatr Psychiatry Neurol. 2008 Jun;21(2):123-32. doi: 10.1177/0891988708316862.

41.

Transcranial ultrasound in Parkinson's disease.

Stern MB.

Lancet Neurol. 2008 May;7(5):376-8. doi: 10.1016/S1474-4422(08)70068-1. Epub 2008 Apr 3. No abstract available.

PMID:
18394966
42.

Laser-fabricated glass microlens arrays.

Fritze M, Stern MB, Wyatt PW.

Opt Lett. 1998 Jan 15;23(2):141-3.

PMID:
18084439
43.

Long-term follow-up of impulse control disorders in Parkinson's disease.

Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, Weintraub D.

Mov Disord. 2008 Jan;23(1):75-80.

44.

Potential outcome measures and trial design issues for multiple system atrophy.

May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW; North American Multiple System Atrophy Study Group.

Mov Disord. 2007 Dec;22(16):2371-7.

45.

Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease.

Siderowf A, Jennings D, Connolly J, Doty RL, Marek K, Stern MB.

Mov Disord. 2007 Nov 15;22(15):2249-55.

PMID:
17876851
46.

Phenylthiocarbamide (PTC) perception in Parkinson disease.

Moberg PJ, Balderston CC, Rick JH, Roalf DR, Weintraub D, Kleiner-Fisman G, Stern MB, Duda JE.

Cogn Behav Neurol. 2007 Sep;20(3):145-8.

PMID:
17846512
47.

Falling in Parkinson disease: identifying and prioritizing risk factors in recurrent fallers.

Dennison AC, Noorigian JV, Robinson KM, Fisman DN, Cianci HJ, Moberg P, Bunting-Perry L, Martine R, Duda J, Stern MB.

Am J Phys Med Rehabil. 2007 Aug;86(8):621-32.

PMID:
17667192
48.

Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life.

Kleiner-Fisman G, Liang GS, Moberg PJ, Ruocco AC, Hurtig HI, Baltuch GH, Jaggi JL, Stern MB.

J Neurosurg. 2007 Jul;107(1):29-36.

PMID:
17639870
49.

Intervening in the neuropsychiatric features of Parkinson's disease.

Weintraub D, Stern MB.

Expert Rev Neurother. 2007 Jun;7(6):699-710. Review.

PMID:
17563252
50.

Effect of age on geriatric depression scale performance in Parkinson's disease.

Weintraub D, Saboe K, Stern MB.

Mov Disord. 2007 Jul 15;22(9):1331-5.

Supplemental Content

Loading ...
Support Center